首页> 美国卫生研究院文献>Micromachines >Preparation of an Acridinium Ester-Labeled Antibody and Its Application in GoldMag Nanoparticle-Based Ultrasensitive Chemiluminescence Immunoassay for the Detection of Human Epididymis Protein 4
【2h】

Preparation of an Acridinium Ester-Labeled Antibody and Its Application in GoldMag Nanoparticle-Based Ultrasensitive Chemiluminescence Immunoassay for the Detection of Human Epididymis Protein 4

机译:cri啶酯标记的抗体的制备及其在基于GoldMag纳米粒子的超灵敏化学发光免疫分析中检测人附睾蛋白4的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

An ultrasensitive and rapid sandwich-type chemiluminescence immunoassay (CLIA) was developed for the clinical determination of human epididymis protein 4 (HE4) in human serum, using GoldMag nanoparticles as solid phase and acridinium ester (AE) as chemiluminescence system (GMP-CLIA). The process of AE labeling antibodies was systematically studied and evaluated. The effect of varies factors such as molar ratio of AE to antibodies, labeling time, and the components of elution buffer and trigger solution were optimized. Under the selected conditions, AE labeling experiments were successfully performed with the average labeling efficiency of 1.92 ± 0.08, and antibody utilization rate of 69.77 ± 1.19%. Antibody activity remained unchanged after labeling. The established GMP-CLIA method can detect HE4 in the range of 0.25–50 ng·mL−1 (10–2000 pM) with a detection limit of 0.084 ng·mL−1 (3.36 pM). The sensitivity has reached a high level, comparable with the current commercial detection kits. This proposed method has been successfully applied to the clinical determination of HE4 in 65 human sera. The results showed a good correlation with a clinical method, microplate-based chemiluminescence enzyme immunoassay (CLEIA), with the correlation coefficient of 0.9594.
机译:开发了一种超灵敏,快速的夹心型化学发光免疫分析法(CLIA),以GoldMag纳米颗粒为固相,protein啶酸酯(AE)作为化学发光系统(GMP-CLIA),用于临床测定人血清中的人类附睾蛋白4(HE4)。 。对AE标记抗体的过程进行了系统的研究和评估。优化了各种因素的影响,如AE与抗体的摩尔比,标记时间以及洗脱缓冲液和触发溶液的成分。在所选条件下,成功进行了AE标记实验,平均标记效率为1.92±0.08,抗体利用率为69.77±1.19%。标记后抗体活性保持不变。建立的GMP-CLIA方法可以检测到0.25–50 ng·mL -1 (10–2000 pM)范围内的HE4,检测限为0.084 ng·mL -1 (3.36 pM)。灵敏度已达到与当前商用检测套件相当的水平。该方法已成功应用于65人血清中HE4的临床测定。结果显示与临床方法,基于微孔板的化学发光酶免疫法(CLEIA)的相关性很好,相关系数为0.9594。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号